Data as of Nov 17, 2026 close · Statements through the quarter ended Mar 2026 · Source: Financial Modeling Prep (methodology)
OKYO Pharma Limited most recently reported annual revenue of 0, a net loss of 9.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
OKYO Pharma Limited: net profit was positive in 0 of 10 reported years; the most recent year shows a net loss of 9.0M.
Income Statement — 10 Years (millions, reporting currency)
Metric
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Revenue
0
0
0
0
0
0
0
0
0
0
Operating Expenses
0
28.0M
5.0M
2.0M
4.0M
6.0M
13.0M
16.0M
7.0M
8.0M
Operating Profit
0
−28.0M
−5.0M
−2.0M
−4.0M
−6.0M
−13.0M
−16.0M
−7.0M
−8.0M
Other Income
0
0
0
0
1.0M
0
0
−1.0M
−1.0M
0
Interest
0
0
0
0
0
0
0
1.0M
1.0M
0
Depreciation
0
1.0M
0
0
0
0
0
0
0
0
Profit Before Tax
0
−28.0M
−5.0M
−2.0M
−3.0M
−6.0M
−13.0M
−17.0M
−8.0M
−9.0M
Tax rate (%)
0.0%
0.0%
0.0%
4.7%
0.7%
12.7%
0.1%
-0.1%
41.0%
-0.1%
Net Profit
0
−28.0M
−5.0M
−2.0M
−3.0M
−5.0M
−13.0M
−17.0M
−5.0M
−9.0M
EPS
−0.04
−4.80
−0.62
−0.17
−0.32
−0.36
−0.60
0.00
−0.12
−0.24
Quarterly Results — Last 12 Quarters (millions, reporting currency)
8 duplicate period labels in the source data were collapsed.
Metric
Sep '20
Mar '21
Sep '21
Mar '22
Sep '22
Mar '23
Sep '23
Mar '24
Sep '24
Mar '25
Sep '25
Mar '26
Revenue
0
0
0
0
0
0
0
0
0
0
0
0
Operating Expenses
1.0M
3.0M
3.0M
7.0M
6.0M
0
9.0M
0
3.0M
4.0M
3.0M
6.0M
Operating Profit
−1.0M
−3.0M
−3.0M
−7.0M
−6.0M
0
−9.0M
0
−3.0M
−4.0M
−3.0M
−6.0M
Interest
0
0
0
0
0
0
0
0
1.0M
0
0
0
Profit Before Tax
−1.0M
−3.0M
−3.0M
−7.0M
−6.0M
0
−9.0M
0
−4.0M
−4.0M
−3.0M
−6.0M
Tax rate (%)
-0.0%
0.9%
6.9%
17.0%
0.0%
0.2%
-0.9%
-0.8%
34.6%
47.7%
0.0%
-0.1%
Net Profit
−1.0M
−3.0M
−3.0M
−6.0M
−6.0M
0
−9.0M
0
−3.0M
−2.0M
−3.0M
−6.0M
EPS
−0.11
−0.27
0.00
−0.36
0.00
0.00
0.00
0.00
−0.08
−0.04
−0.07
−0.17
Over the 10 years reported for OKYO Pharma Limited, cash stood at 15.0M in the latest year, shareholders' equity was 174.0M, current assets covered current liabilities 2.33 times.
Balance Sheet — 10 Years (millions, reporting currency)
Metric
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Total Assets
0
0
1.0M
1.0M
7.0M
4.0M
5.0M
2.0M
4.0M
21.0M
Current Assets
17.0M
0
1.0M
1.0M
7.0M
4.0M
5.0M
2.0M
4.0M
21.0M
Cash
0
0
1.0M
0
7.0M
3.0M
4.0M
1.0M
2.0M
15.0M
Inventory
0
0
0
0
0
0
0
0
0
0
Receivables
0
0
0
0
0
1.0M
1.0M
1.0M
2.0M
0
Fixed Assets
0
0
0
0
0
0
0
0
0
0
Capital Work in Progress
0
0
0
0
0
0
0
0
0
0
Investments
17.0M
0
0
0
0
0
0
0
0
6.0M
Other Assets
0
0
0
0
0
0
0
0
0
0
Total Liabilities
0
0
0
1.0M
2.0M
1.0M
7.0M
7.0M
9.0M
9.0M
Current Liabilities
0
0
0
1.0M
2.0M
1.0M
7.0M
7.0M
9.0M
9.0M
Borrowings
0
0
0
0
0
0
2.0M
0
0
0
Other Liabilities
0
0
0
1.0M
2.0M
1.0M
5.0M
7.0M
9.0M
9.0M
Equity
0
0
89.0M
0
0
124.0M
0
0
0
174.0M
Reserves
0
0
0
0
5.0M
3.0M
−2.0M
−6.0M
−6.0M
12.0M
For OKYO Pharma Limited, operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at 6.0M; free cash flow was positive in 0 of 10 years.
Cash Flow Statement — 10 Years (millions, reporting currency)
OKYO Pharma Limited (OKYO) reported annual revenue of 0 in its most recent fiscal year.
What is OKYO Pharma Limited's net profit?
OKYO Pharma Limited (OKYO) reported a net loss of 9.0M in its most recent fiscal year.
What is OKYO EV/EBITDA?
OKYO Pharma Limited's enterprise value to EBITDA (EV/EBITDA) ratio is -6.57. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Biotechnology stocks